Nath Bio-Genes (India) Ltd (NATHBIOGEN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 628630,
    "name": "Nath Bio-Genes",
    "stock_name": "Nath Bio-Genes",
    "full_name": "Nath Bio-Genes (India) Ltd",
    "name_url": "stocks-analysis/nath-bio-genes",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "149.00",
    "chg": -4.65,
    "chgp": "-3.03%",
    "dir": -1,
    "prev_price": "153.65",
    "mcapval": "292.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 537291,
    "symbol": "NATHBIOGEN",
    "ind_name": "Other Agricultural Products",
    "ind_code": 107,
    "indexname": "",
    "isin": "INE448G01010",
    "curr_date": "Feb 11",
    "curr_time": "",
    "bse_nse_vol": "27.52 k",
    "exc_status": "Active",
    "traded_date": "Feb 11, 2026",
    "traded_date_str": "2026 02 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nath-bio-genes-628630-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Nath Bio-Genes (India) Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-india-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-3821855",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/NathBioGenesInd_mojoScore_3821855.png",
        "date": "2026-02-05 08:19:45",
        "description": "Nath Bio-Genes (India) Ltd, a player in the Other Agricultural Products sector, has seen its investment rating downgraded from Strong Sell to Sell as of 4 February 2026. This adjustment reflects a nuanced shift in the company’s technical outlook, valuation, financial trends, and overall quality metrics, signalling caution for investors despite some pockets of valuation attractiveness."
      },
      {
        "title": "Are Nath Bio-Genes (India) Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-nath-bio-genes-india-ltd-latest-results-good-or-bad-3815009",
        "imagepath": "",
        "date": "2026-02-01 19:14:19",
        "description": "Nath Bio-Genes (India) Ltd's latest financial results for Q3 FY26 present a complex picture characterized by significant revenue growth juxtaposed with deteriorating profitability metrics. The company reported net sales of ₹65.96 crores, reflecting a substantial year-on-year growth of 78.90%. This growth is largely attributed to the seasonal demand typical in the agricultural sector, particularly during the peak agricultural season. However, despite this topline growth, the net profit fell to ₹1.60 crores, marking a decline of 39.62% compared to the previous year.\n\nThe operational challenges are evident in the company's operating margin, which collapsed to 5.43% from 21.81% a year earlier, indicating severe margin compression. This decline in profitability is compounded by rising interest costs, which reached ₹4.54 crores, consuming a significant portion of the operating profit. The interest burden has rais..."
      },
      {
        "title": "Are Nath Bio-Genes (India) Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-nath-bio-genes-india-ltd-latest-results-good-or-bad-3813334",
        "imagepath": "",
        "date": "2026-01-31 19:23:06",
        "description": "Nath Bio-Genes (India) Ltd's latest financial results reveal a complex picture of operational performance marked by significant volatility. In the quarter ended September 2025, the company reported net sales of ₹43.85 crores, which reflects a notable year-on-year growth of 36.22% compared to ₹32.19 crores in the same quarter last year. However, this figure represents a substantial decline of 84.54% from the preceding quarter's sales of ₹283.70 crores, highlighting the seasonality inherent in its agricultural products business.\n\nThe net profit for the same quarter was ₹2.75 crores, showing a remarkable year-on-year increase of 147.75% from ₹1.11 crores in Q2 FY25. Conversely, it experienced a sharp decline of 92.62% compared to the previous quarter's profit of ₹37.28 crores. This extreme fluctuation underscores the challenges in assessing the company's performance on a quarter-to-quarter basis.\n\nThe operatin..."
      },
      {
        "title": "Nath Bio-Genes Q3 FY26: Seasonal Surge Masks Profitability Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/nath-bio-genes-q3-fy26-seasonal-surge-masks-profitability-concerns-3813264",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NathBioGenesInd_quaterlyResult_3813264.png",
        "date": "2026-01-31 18:31:39",
        "description": "Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹271.00 crores, reported a consolidated net profit of ₹1.60 crores for Q3 FY26 (October-December 2025), representing a sharp 66.80% decline quarter-on-quarter and a 39.62% fall year-on-year. Despite a robust 78.90% YoY revenue increase to ₹65.96 crores driven by seasonal demand, the company's profitability deteriorated significantly as operating margins compressed and interest costs surged to their highest quarterly levels."
      },
      {
        "title": "Nath Bio-Genes (India) Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-india-ltd-is-rated-strong-sell-3805186",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NathBioGenesInd_mojoScore_3805186.png",
        "date": "2026-01-27 10:10:49",
        "description": "Nath Bio-Genes (India) Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 07 Jan 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 27 January 2026, providing investors with the latest perspective on the company’s performance and prospects."
      },
      {
        "title": "Nath Bio-Genes (India) Ltd Hits 52-Week Low Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nath-bio-genes-india-ltd-hits-52-week-low-amidst-continued-downtrend-3796734",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NathBioGenesInd_priceRelatedfactors_3796734.png",
        "date": "2026-01-20 15:15:43",
        "description": "Nath Bio-Genes (India) Ltd’s shares declined sharply to a new 52-week low of Rs.139.8 on 20 Jan 2026, marking a significant downturn amid broader market weakness and sectoral pressures. The stock underperformed its sector and key market indices, reflecting ongoing concerns about the company’s financial performance and investor sentiment."
      },
      {
        "title": "Nath Bio-Genes (India) Ltd Upgraded to Sell on Technical Improvements and Valuation Appeal",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-india-ltd-upgraded-to-sell-on-technical-improvements-and-valuation-appeal-3781070",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NathBioGenesInd_mojoScore_3781070.png",
        "date": "2026-01-05 08:11:14",
        "description": "Nath Bio-Genes (India) Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 2 January 2026, driven primarily by a shift in technical indicators despite ongoing fundamental challenges. The company’s Mojo Score now stands at 31.0, reflecting a cautious but improved outlook amid mixed financial and market signals."
      },
      {
        "title": "Nath Bio-Genes (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-india-ltd-is-rated-sell-3779836",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NathBioGenesInd_mojoScore_3779836.png",
        "date": "2026-01-03 10:10:34",
        "description": "Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 January 2026, providing investors with the most recent and relevant data to assess the company's outlook."
      },
      {
        "title": "Nath Bio-Genes (India) Faces Challenging Market Assessment Amidst Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3766672",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NathBioGenesInd_mojoScore_3766672.png",
        "date": "2025-12-23 08:45:09",
        "description": "Nath Bio-Genes (India), a player in the Other Agricultural Products sector, has experienced a shift in market evaluation driven by a combination of technical indicators, valuation metrics, financial trends, and broader market participation. This article analyses the factors influencing the recent revision in the company’s assessment, highlighting key data points and contextualising its performance against sector and market benchmarks."
      }
    ],
    "total": 141,
    "sid": "628630",
    "stock_news_url": "https://www.marketsmojo.com/news/nath-bio-genes-india-628630"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "31-Jan-2026",
      "details": "Investor Presentation of Financial Results as on 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Outcome Of Board Meeting",
      "datetime": "31-Jan-2026",
      "details": "Financial Results as on 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
      "datetime": "31-Jan-2026",
      "details": "Issue of Duplicate Share Certificate",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Nath Bio-Genes (India) Ltd has declared <strong>20%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Nath Bio-Genes (India) Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

2026-02-05 08:19:45

Nath Bio-Genes (India) Ltd, a player in the Other Agricultural Products sector, has seen its investment rating downgraded from Strong Sell to Sell as of 4 February 2026. This adjustment reflects a nuanced shift in the company’s technical outlook, valuation, financial trends, and overall quality metrics, signalling caution for investors despite some pockets of valuation attractiveness.

Read full news article

Are Nath Bio-Genes (India) Ltd latest results good or bad?

2026-02-01 19:14:19

Nath Bio-Genes (India) Ltd's latest financial results for Q3 FY26 present a complex picture characterized by significant revenue growth juxtaposed with deteriorating profitability metrics. The company reported net sales of ₹65.96 crores, reflecting a substantial year-on-year growth of 78.90%. This growth is largely attributed to the seasonal demand typical in the agricultural sector, particularly during the peak agricultural season. However, despite this topline growth, the net profit fell to ₹1.60 crores, marking a decline of 39.62% compared to the previous year. The operational challenges are evident in the company's operating margin, which collapsed to 5.43% from 21.81% a year earlier, indicating severe margin compression. This decline in profitability is compounded by rising interest costs, which reached ₹4.54 crores, consuming a significant portion of the operating profit. The interest burden has rais...

Read full news article

Are Nath Bio-Genes (India) Ltd latest results good or bad?

2026-01-31 19:23:06

Nath Bio-Genes (India) Ltd's latest financial results reveal a complex picture of operational performance marked by significant volatility. In the quarter ended September 2025, the company reported net sales of ₹43.85 crores, which reflects a notable year-on-year growth of 36.22% compared to ₹32.19 crores in the same quarter last year. However, this figure represents a substantial decline of 84.54% from the preceding quarter's sales of ₹283.70 crores, highlighting the seasonality inherent in its agricultural products business. The net profit for the same quarter was ₹2.75 crores, showing a remarkable year-on-year increase of 147.75% from ₹1.11 crores in Q2 FY25. Conversely, it experienced a sharp decline of 92.62% compared to the previous quarter's profit of ₹37.28 crores. This extreme fluctuation underscores the challenges in assessing the company's performance on a quarter-to-quarter basis. The operatin...

Read full news article

Nath Bio-Genes Q3 FY26: Seasonal Surge Masks Profitability Concerns

2026-01-31 18:31:39

Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹271.00 crores, reported a consolidated net profit of ₹1.60 crores for Q3 FY26 (October-December 2025), representing a sharp 66.80% decline quarter-on-quarter and a 39.62% fall year-on-year. Despite a robust 78.90% YoY revenue increase to ₹65.96 crores driven by seasonal demand, the company's profitability deteriorated significantly as operating margins compressed and interest costs surged to their highest quarterly levels.

Read full news article

Nath Bio-Genes (India) Ltd is Rated Strong Sell

2026-01-27 10:10:49

Nath Bio-Genes (India) Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 07 Jan 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 27 January 2026, providing investors with the latest perspective on the company’s performance and prospects.

Read full news article

Nath Bio-Genes (India) Ltd Hits 52-Week Low Amidst Continued Downtrend

2026-01-20 15:15:43

Nath Bio-Genes (India) Ltd’s shares declined sharply to a new 52-week low of Rs.139.8 on 20 Jan 2026, marking a significant downturn amid broader market weakness and sectoral pressures. The stock underperformed its sector and key market indices, reflecting ongoing concerns about the company’s financial performance and investor sentiment.

Read full news article

Nath Bio-Genes (India) Ltd Upgraded to Sell on Technical Improvements and Valuation Appeal

2026-01-05 08:11:14

Nath Bio-Genes (India) Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 2 January 2026, driven primarily by a shift in technical indicators despite ongoing fundamental challenges. The company’s Mojo Score now stands at 31.0, reflecting a cautious but improved outlook amid mixed financial and market signals.

Read full news article

Nath Bio-Genes (India) Ltd is Rated Sell

2026-01-03 10:10:34

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 January 2026, providing investors with the most recent and relevant data to assess the company's outlook.

Read full news article

Nath Bio-Genes (India) Faces Challenging Market Assessment Amidst Mixed Financial and Technical Signals

2025-12-23 08:45:09

Nath Bio-Genes (India), a player in the Other Agricultural Products sector, has experienced a shift in market evaluation driven by a combination of technical indicators, valuation metrics, financial trends, and broader market participation. This article analyses the factors influencing the recent revision in the company’s assessment, highlighting key data points and contextualising its performance against sector and market benchmarks.

Read full news article

View All News